We are pleased to present our poster highlighting safety and first efficacy results of our Xla1 biotherapy targeting obesity and its associated metabolic disorders.
In the same category
Selection of a novel strain of Christensenella minuta as a future biotherapy for Crohn’s disease
Apr 11, 2022more +
Species-targeted sorting and cultivation of commensal bacteria from the gut microbiome using flow...
Feb 16, 2022more +
Next Generation Microbiome Research: Identification of Keystone Species in the Metabolic Regulation...
Sep 1, 2021more +